iNtODEWORLD | Opening New Era in Anti-Fugal Agent (iN-EYD34)
16167
page,page-id-16167,page-template,page-template-full_width,page-template-full_width-php,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

A NEW TYPE ANTIFUNGAL AGENT

iN-EYD34

AN AGING POPULATION COMBINED WITH MORE FREQUENT ORGAN TRANSPLANTS HAS LED TO AN INCREASE IN THE NUMBER OF IMMUNO-COMPROMISED PERSONS IN THE WORLD. AS A RESULT, IT HAS BEEN REPORTED THAT FUNGAL INFECTION INCIDENCES HAVE INCREASED DRAMATICALLY IN RECENT YEARS.
HOWEVER, THE CURRENTLY PRESCRIBED ANTIFUNGAL AGENTS HAVE FLAWS WITH RESPECT TO THEIR GENERAL EFFECTIVENESS AND SAFETY. OF PARTICULAR CONCERN, LONG TERM DOSAGES ARE KNOWN TO COMMONLY BE ASSOCIATED WITH SERIOUS SIDE EFFECTS.
THEREFORE, THERE IS A GREAT NEED TO DEVELOP A NEW ANTIFUNGAL AGENT WITH A MUCH BETTER SAFETY PROFILE COMPARED TO CONVENTIONAL ANTIFUNGAL AGENTS.

ANTIFUNGAL AGENT DEVELOPMENT BY INTRON BIOTECHNOLOGY

iNtRON BIO IS DEVELOPING A NEW TYPE OF ANTIFUNGAL AGENT WITH A POLYKETIDE STRUCTURE WE HAVE LABELED IN-EYD34.
iN-EYD34 HAS A FUNDAMENTALLY DIFFERENT MODE OF ACTION, AND A SAFER PROFILE COMPARED TO PREEXISTING ANTIFUNGAL AGENTS GENERALLY USED (E.G., POLYENE AND AZOLE).

 

– iN-EYD34 demonstrates a powerful level of antifungal activity against a number of clinical isolates obtained from patients suffering from Candidasis (which is the most common fungal infection set in clinical settings) and Criptococcosis (which causes 6 million deaths annually).

– Toxicity tests using Galleria Mellonella demonstrated iN-EYD34 to be highly safe.

TARGET MARKET

ACCORDING TO THE BCC RESEARCH REPORT (2014), AS FOLLOWS:

 

  • “Antifungal drug: Technologies and Global Markets”, the global market for human antifungal agents reached nearly $11.6 billion in 2012 and $11.8 billion in 2013.
  • This market is expected to grow to nearly $13.9 billion in 2018 with a compound annual growth RATE (CAGR) of 3.2% over the five-year period from 2013 to 2018.
  • The U.S. human antifungal agent market reached nearly $4.9 billion in 2013. It is projected to grow to $5.5 billion in 2018 with a CAGR of 2.7% over the five-year period from 2013 to 2018.
  • The Europ human antifungal agent market reached $3.9 billion in 2013. It is projected to grow to $4.4 billion in 2018 with a CAGR od 2.6% over the five-year period from 2013 to 2018.
bsetnr3

iNtRON’s iN-EYD34 will be developed to treat

 

Broad spectrum Systemic or local Antifungal infection
iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.